LACTOLOGY FOUNDATION

Troxipide (ATC A02BX11) is a non-antisecretory gastric cytoprotective agent used for peptic ulcer disease and gastritis, but it is largely obsolete in modern practice and is not recommended during breastfeeding due to potential gastrointestinal toxicity in the nursing infant. In toxicology terms it has a wide therapeutic index but can cause local mucosal irritation, and in lactology it is best classified as contraindicated during lactation (high-risk category, avoid use).file+2

Pharmacological profile

Troxipide is classified in the ATC system as A02BX11, in the group of “other drugs for peptic ulcer and gastro‑oesophageal reflux disease (GORD)” and functions as a systemic gastric mucosal protectant. It does not reduce gastric acid secretion but exerts cytoprotective effects by enhancing gastric mucus production, stimulating cytoprotective prostaglandins, supporting collagen regeneration, improving mucosal blood flow and metabolism, and reducing inflammatory mediator–induced neutrophil activation and reactive oxygen species generation.kegg+3

Troxipide is a benzamide derivative with an approximate molecular weight of about 294 Da, a size that allows systemic distribution and potential excretion into breast milk. It is marketed in some East Asian countries and India under various trade names (for example Aplace, Shuqi, Defensa, Troxip) mainly for gastric ulcer, acute gastritis, and acute exacerbations of chronic gastritis.wikipedia+4

Therapeutic indications and dosing

Clinically, troxipide is indicated for treatment of gastric ulcers and for amelioration of gastric mucosal lesions such as erosions, hemorrhage, redness, and edema in acute gastritis and acute exacerbations of chronic gastritis. It is also used in some markets for symptomatic management of gastro‑oesophageal reflux disease (GERD), heartburn, and erosive oesophagitis.apollopharmacy+3

A commonly recommended adult regimen is 100 mg orally three times daily, usually after meals, with typical treatment durations of 8 to 12 weeks in peptic ulcer or gastritis protocols. The drug is currently not licensed or marketed in Bulgaria and has been largely replaced in many settings by more effective and better studied agents such as proton pump inhibitors and modern H2‑receptor antagonists.pubchem.ncbi.nlm.nih+4

Toxicology and safety profile

General toxicity

Experimental data show an acute oral median lethal dose (LD50) for troxipide of about 2100 mg/kg in animals, indicating a relatively wide therapeutic index compared with its usual clinical doses. In controlled clinical use troxipide is generally well tolerated, with low rates of serious systemic toxicity reported in trials and post‑marketing experience.shijiebiaopin+2

Nevertheless, troxipide has a well‑recognized local irritant effect on mucous membranes, including the oropharyngeal and ocular surfaces, where direct contact can produce acute irritation. Inhalational exposure is associated with risk of acute chemical pneumonitis, reflecting its capacity to injure respiratory mucosa when delivered via a non‑enteral route.file+1

Adverse effects and special risks

The most frequently described adverse reactions are mild to moderate gastrointestinal symptoms such as constipation, abdominal distension, and nonspecific stomach discomfort, alongside occasional liver enzyme elevations such as increased AST (GOT). Prolonged intake has been associated with a risk of Clostridioides difficile–associated diarrhea, especially in predisposed patients, so persistent or severe diarrhea warrants discontinuation and evaluation.zuventus+2

From a broader toxicological perspective, troxipide’s risk profile compares favorably with many older anti‑ulcer regimens because it lacks significant systemic organ toxicity at therapeutic doses, but its limited modern use and modest evidence base should be considered. Modern alternatives with better characterized safety (for example proton pump inhibitors and H2‑blockers) are typically preferred, especially in vulnerable populations such as pregnant or lactating women.drugs.ncats+2

Use in pregnancy

No formal FDA pregnancy category has been assigned to troxipide, and high‑quality human pregnancy data are lacking. In the absence of robust teratogenicity data and given the availability of better studied alternatives, troxipide should generally be avoided in pregnancy unless no safer option is suitable and potential benefits clearly outweigh theoretical risks.mayoclinic+2

Because its mechanism is mainly local cytoprotection and it does not significantly alter systemic hemodynamics or endocrine pathways, major systemic fetal toxicity is not anticipated at usual doses, but this remains theoretical rather than evidence‑based. Standard risk‑reduction measures include preferring agents with established pregnancy safety data, using the minimal effective dose, and restricting duration when therapy is unavoidable.drugbank+2

Lactation pharmacology

Given its molecular weight around 294 Da and systemic absorption, troxipide is expected to be at least partially excreted into breast milk, even though no pharmacokinetic studies have quantified milk levels or relative infant doses. In the absence of specific lactation pharmacokinetic data, general principles of drug transfer into milk suggest that a low‑molecular‑weight, non‑ionized, moderately lipophilic compound with systemic exposure may reach the nursing infant in clinically relevant amounts, particularly with repeated dosing.mayoclinic+3

The key concern in breastfed infants is the potential for troxipide to induce a toxic gastroenteritis or other gastrointestinal irritation, given its known local mucosal irritant properties and primary site of action in the GI tract. Additional theoretical risks include alterations in neonatal gastric mucosal defense or microbiota, particularly because data on neonatal tolerance to this specific cytoprotective agent are lacking.zuventus+3

Lactation risk assessment and categorization

On toxicological–lactological grounds, troxipide is best classified as unsuitable during breastfeeding, corresponding to a high‑risk or “avoid” category such as category IV in a restrictive lactation classification system. The combination of expected milk penetration, lack of infant safety data, and plausible risk of gastrointestinal toxicity in neonates and young infants justifies a categorical recommendation against use during lactation.mayoclinic+1

In contrast to many common medications for acid‑related disorders and infections that have been well studied and are considered compatible with breastfeeding, troxipide lacks reassuring evidence and offers no clear advantage over safer alternatives for lactating women. Therefore, in breastfeeding patients requiring therapy for peptic ulcer disease, gastritis, or GERD, evidence‑based alternatives with established lactation safety should be chosen instead of troxipide.hse+1

Clinical recommendations for breastfeeding

For breastfeeding women with dyspepsia, gastritis, or GERD, non‑pharmacological measures (for example dietary modification and positional changes) and extensively studied acid‑suppressing agents such as omeprazole and other proton pump inhibitors, as well as H2‑receptor antagonists and certain antacids, are generally preferred and can often be used safely under medical supervision. When pharmacotherapy is necessary, drugs with published data on breast milk transfer and infant outcomes should be prioritized, and troxipide should not be initiated or continued.hse+2

If a mother has already received troxipide while breastfeeding, careful clinical monitoring of the infant for signs of gastrointestinal distress, poor feeding, or unusual irritability is advisable, and consultation with a specialist in clinical pharmacology, toxicology, or lactation medicine should be sought. In situations where high‑dose or prolonged troxipide therapy has already occurred, consideration may be given to temporary cessation of breastfeeding and substitution with expressed, previously stored milk or formula until maternal drug elimination is complete, guided by local expert recommendations.mayoclinic+1

Regulatory and practical considerations

Troxipide is not registered in Bulgaria and remains a niche product even in countries where it is marketed, reflecting both its limited evidence base and the dominance of more effective contemporary therapies. For clinicians practicing in regions where troxipide is available, it should be reserved for selected non‑pregnant, non‑lactating adults when conventional therapy is unsuitable and when its cytoprotective profile offers a clear benefit.wikipedia+2

From a public health and educational perspective, highlighting troxipide as an example of a “legacy” gastric cytoprotective agent that is inappropriate in breastfeeding aligns with broader efforts to reduce neonatal exposure to inadequately studied medications and to promote a lower‑toxicity environment for infants. Educational materials and formularies should clearly mark troxipide as contraindicated during lactation and emphasize safer, evidence‑based alternatives for acid‑related disorders in breastfeeding women.file+2